Molekulargenetische Diagnostik
Praxis Dr. Mato Nagel

Nicht-medulläres Schilddrüsenkarzinom

Das nicht-medulläres Schilddrüsenkarzinom ist eine heterogene autosomal dominante Erkrankung der follikulären Schilddrüsenzellen.

Gliederung

Schilddrüsenkarzinome
Familiäres meduläres Schilddrüsenkarzinom
Nicht-medulläres Schilddrüsenkarzinom
Familiäres folliculäres Schilddrüsenkarzinom
MINPP1
Folliculäres Schilddrüsenkarzinom
HRAS
NRAS
Nicht-medulläres Schilddrüsenkarzinom 1
NKX2-1
Nicht-medulläres Schilddrüsenkarzinom 2
SRGAP1
Nicht-medulläres Schilddrüsenkarzinom 3
Nicht-medulläres Schilddrüsenkarzinom 4
FOXE1
Nicht-medulläres Schilddrüsenkarzinom 5
HABP2

Referenzen:

1.

Klugbauer S et. al. (1999) The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas.

[^]
2.

Klugbauer S et. al. (1998) Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5.

[^]
3.

Nikiforova MN et. al. (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

[^]
4.

Kroll TG et. al. (2000) PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected].

[^]
5.

Dwight T et. al. (2003) Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors.

[^]
6.

Ngan ES et. al. (2009) A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.

[^]
7.

Fortunati N et. al. (2004) Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells.

[^]
8.

Bongarzone I et. al. (1994) Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas.

[^]
9.

Takami H et. al. (1996) Familial nonmedullary thyroid cancer: an emerging entity that warrants aggressive treatment.

[^]
10.

Burgess JR et. al. (1997) Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid.

[^]
11.

Pierotti MA et. al. (1996) Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells.

[^]
12.

Bongarzone I et. al. (1997) Comparison of the breakpoint regions of ELE1 and RET genes involved in the generation of RET/PTC3 oncogene in sporadic and in radiation-associated papillary thyroid carcinomas.

[^]
13.

Learoyd DL et. al. (1998) RET/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas.

[^]
14.

Sugg SL et. al. (1998) Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia.

[^]
15.

Canzian F et. al. (1998) A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2.

[^]
16.

Lesueur F et. al. (1999) Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium.

[^]
17.

Trovato M et. al. (1999) Loss of heterozygosity of the long arm of chromosome 7 in follicular and anaplastic thyroid cancer, but not in papillary thyroid cancer.

[^]
18.

Thomas GA et. al. (1999) High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant.

[^]
19.

Fenton CL et. al. (2000) The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults.

[^]
20.

Chua EL et. al. (2000) Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia.

[^]
21.

Corvi R et. al. (2000) RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma.

[^]
22.

Klein M et. al. (2001) Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma.

[^]
23.

Hrafnkelsson J et. al. (2001) Familial non-medullary thyroid cancer in Iceland.

[^]
24.

Elisei R et. al. (2001) RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults.

[^]
25.

Kitamura Y et. al. (2001) Allelotyping of follicular thyroid carcinoma: frequent allelic losses in chromosome arms 7q, 11p, and 22q.

[^]
26.

Mechler C et. al. (2001) Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.

[^]
27.

Savagner F et. al. (2002) Analysis of Tg transcripts by real-time RT-PCR in the blood of thyroid cancer patients.

[^]
28.

Carlomagno F et. al. (2002) The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes.

[^]
29.

Finn SP et. al. (2003) Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma.

[^]
30.

Baudin E et. al. (2003) Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.

[^]
31.

Kimura ET et. al. (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

[^]
32.

Carlomagno F et. al. (2003) Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).

[^]
33.

Namba H et. al. (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.

[^]
34.

Xing M et. al. (2004) Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer.

[^]
35.

Weber F et. al. (2005) Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis.

[^]
36.

Ciampi R et. al. (2005) Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.

[^]
37.

Wagner K et. al. (2005) Thyrotropin receptor/thyroglobulin messenger ribonucleic acid in peripheral blood and fine-needle aspiration cytology: diagnostic synergy for detecting thyroid cancer.

[^]
38.

Sarquis MS et. al. (2006) High frequency of loss of heterozygosity in imprinted, compared with nonimprinted, genomic regions in follicular thyroid carcinomas and atypical adenomas.

[^]
39.

García-Rostán G et. al. (2005) Mutation of the PIK3CA gene in anaplastic thyroid cancer.

[^]
40.

Zhu Z et. al. (2006) Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity.

[^]
41.

Frau DV et. al. (2008) Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings.

[^]
42.

Abubaker J et. al. (2008) Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.

[^]
43.

Liu Z et. al. (2008) Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.

[^]
44.

Gudmundsson J et. al. (2009) Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations.

[^]
45.

Vriens MR et. al. (2009) Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer.

[^]
46.

Takahashi M et. al. (2010) The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl.

[^]
47.

Bonora E et. al. (2010) Genetic Predisposition to Familial Nonmedullary Thyroid Cancer: An Update of Molecular Findings and State-of-the-Art Studies.

[^]
48.

Jendrzejewski J et. al. (2012) The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type.

[^]
49.

Gara SK et. al. (2015) Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer.

[^]
50.

Gara SK et. al. (2015) HABP2 Mutation and Nonmedullary Thyroid Cancer.

[^]
51.

Zhou EY et. al. (2015) HABP2 Mutation and Nonmedullary Thyroid Cancer.

[^]
52.

Sponziello M et. al. (2015) HABP2 Mutation and Nonmedullary Thyroid Cancer.

[^]
53.

Tomsic J et. al. (2015) HABP2 Mutation and Nonmedullary Thyroid Cancer.

[^]
54.

Stoffer SS et. al. (1986) Familial papillary carcinoma of the thyroid.

[^]
55.

Lacour J et. al. (1973) [Papillary epithelioma of the thyroid gland. Apropos of 2 familial cases].

[^]
56.

Flannigan GM et. al. (1983) Simultaneous presentation of papillary carcinoma of thyroid in a father and son.

[^]
57.

Lote K et. al. (1980) Familial occurrence of papillary thyroid carcinoma.

[^]
58.

Phade VR et. al. (1981) Familial papillary carcinoma of the thyroid.

[^]
59.

Grossman RF et. al. (1995) Familial nonmedullary thyroid cancer. An emerging entity that warrants aggressive treatment.

[^]
60.

Harach HR et. al. (1994) Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm.

[^]